{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:53:05Z","timestamp":1795042385698,"version":"4.10.2"},"reference-count":276,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/1744666x.2021.1940962","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T13:31:38Z","timestamp":1623245498000},"page":"835-852","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":179,"title":["The IL-4, IL-13 and IL-31 pathways in atopic dermatitis"],"prefix":"10.1080","volume":"17","author":[{"given":"Celina","family":"Dubin","sequence":"first","affiliation":[{"name":"Department of Dermatology, And Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[{"name":"Department of Dermatology, And Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA"},{"name":"Department of Dermatology, Magna Graecia, Catanzaro, IT, Calabria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology, And Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA"},{"name":"Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1564038"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.032"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.009"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.053"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1195733"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1080\/000155500300012873"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05776.x"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01436.x"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.006"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0138"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21060"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.027"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1563"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.09.008"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2009.10.002"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2010.06.003"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.033"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/all.12343"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.88"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.03.006"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.054"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.06.014"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02326.x"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1566"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/ng1767"},{"key":"cit0028","volume-title":"Cornification of the skin: a non\u2010apoptotic cell death mechanism","author":"Candi E","year":"2009"},{"key":"cit0029","doi-asserted-by":"crossref","unstructured":"Van Smeden J, Bouwstra JA. Stratum corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients. Skin barrier function. Vol. 49. Karger Publishers, Basel; 2016. p. 8\u201326.","DOI":"10.1159\/000441540"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-016-0158-5"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13514"},{"key":"cit0032","volume-title":"Pathophysiology of atopic dermatitis: clinical implications. Allergy and asthma proceedings","author":"Kim J","year":"2019"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.83"},{"issue":"2","key":"cit0034","first-page":"171","volume":"11","author":"Metwally SS","year":"2004","journal-title":"Egypt J Immunol"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-004-0455-6"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/35037014"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.008"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.03.006"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09207-z"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12753"},{"issue":"2","key":"cit0043","first-page":"140","volume":"152","author":"Orfali RL","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20164412"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0413-2"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.048"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1111\/all.13239"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/all.12316"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.013"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901860"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.701"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-0987-9_21"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08522.x"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1021942"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03485.x"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.35.6.502"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2370.2003.00416.x"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2010.01243.x"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01357.x"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(02)00065-8"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.05.010"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12545"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1111\/all.12526"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8252-4"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12635"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1241-3_6"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80010-7"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(91)92154-S"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1333"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7716"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(02)00318-X"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2014.40920"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.10.001"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00167"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S257647"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14014"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15973"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.622126"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.012"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1177\/1753425917732823"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.05.002"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.133"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.74"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.503"},{"issue":"1","key":"cit0087","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-2427(98)00170-6","volume":"88","author":"Gr\u00f6ne A","year":"2002","journal-title":"Vet Immunol Immunopathol"},{"issue":"2","key":"cit0088","first-page":"125","volume":"16","author":"Pastore S","year":"2006","journal-title":"Eur J Dermatol"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2008.00786.x"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-017-0044-7"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14046720"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98006"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-014-0433-9"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S260370"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.10.031"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3262"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.05.127"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.361"},{"issue":"3","key":"cit0099","first-page":"988","volume":"292","author":"Oriente A","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.11.077"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01972-3"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100504"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.10.045"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.10.033"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.5154"},{"issue":"6","key":"cit0107","first-page":"941","volume":"19","author":"Yagi Y","year":"2007","journal-title":"Int J Mol Med"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.003"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2011.07.006"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-014-0423-y"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03794.x"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.05.047"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.02.009"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.07.015"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1191"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01487.x"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301836"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1038\/ni1084"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900712"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029815"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq027"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12222"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1159\/000323307"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.10.005"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-013-1284-2"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2016.1146681"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700231"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02545.x"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25094-4"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2019.04.026"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00515-1"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.013"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.037"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4050858"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.039"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1449642"},{"key":"cit0138","unstructured":"Dose-ranging Study of Nemolizumab in Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03100344."},{"key":"cit0139","unstructured":"A Phase 2 Study of CIM331 for Atopic Dermatitis Patients. https:\/\/ClinicalTrials.gov\/show\/NCT01986933."},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.03.012"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"cit0142","unstructured":"A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema. https:\/\/ClinicalTrials.gov\/show\/NCT00676884"},{"issue":"11","key":"cit0143","first-page":"1286","volume":"11","author":"Antoniu SA","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"cit0144","unstructured":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2). https:\/\/ClinicalTrials.gov\/show\/NCT03160885."},{"key":"cit0145","unstructured":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT04178967."},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.017"},{"key":"cit0147","unstructured":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03985943."},{"key":"cit0148","unstructured":"REGENERON AND SANOFI ANNOUNCE FDA APPROVAL OF DUPIXENT\u00ae (DUPILUMAB), THE FIRST TARGETED BIOLOGIC THERAPY FOR ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS [Internet]. Tarrytown, NY and Paris, FR; 2017"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.060"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18476"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00387-2"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1292134"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1373736"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S133661"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416670364"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1097\/JXX.0000000000000088"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00388-8"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.005"},{"key":"cit0161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01768"},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4040593"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.524203"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61600-6"},{"key":"cit0165","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6179"},{"key":"cit0166","author":"Groves R","year":"2007","journal-title":"J Invest Dermatol"},{"key":"cit0167","unstructured":"Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201 [Internet]. PRNewswire; 2020"},{"key":"cit0168","unstructured":"A Study Assessing the Efficacy and Safety of CBP-201. https:\/\/ClinicalTrials.gov\/show\/NCT04444752."},{"key":"cit0169","unstructured":"A Study of AK120 (IL-4R\u03b1) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT04256174."},{"key":"cit0170","doi-asserted-by":"publisher","DOI":"10.25251\/skin.2.supp.28"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"cit0172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"cit0173","unstructured":"Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT02347176."},{"key":"cit0174","author":"Wollenberg A","year":"2020","journal-title":"Br J Dermatol"},{"key":"cit0175","unstructured":"Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT04587453."},{"key":"cit0176","unstructured":"Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function. https:\/\/ClinicalTrials.gov\/show\/NCT04556461."},{"key":"cit0177","unstructured":"Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). https:\/\/ClinicalTrials.gov\/show\/NCT03526861."},{"key":"cit0178","unstructured":"LEO eyeing 2021 US launch for eczema drug tralokinumab [Internet]. PharmaPhorum; 2020"},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S211032"},{"key":"cit0180","unstructured":"A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT02465606."},{"key":"cit0181","unstructured":"A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT02340234."},{"key":"cit0182","unstructured":"A Study of Lebrikizumab (LY3650150) in Patients With Moderate-to-Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03443024."},{"key":"cit0183","unstructured":"Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1). https:\/\/ClinicalTrials.gov\/show\/NCT04146363."},{"key":"cit0184","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606490"},{"key":"cit0185","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.018"},{"key":"cit0186","unstructured":"Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03989206."},{"key":"cit0187","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12164"},{"key":"cit0188","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137"},{"key":"cit0189","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"cit0190","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215786"},{"key":"cit0191","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"cit0192","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.019"},{"key":"cit0193","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.016"},{"key":"cit0194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"cit0195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.018"},{"key":"cit0196","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0880-2"},{"key":"cit0197","doi-asserted-by":"publisher","DOI":"10.1002\/art.38745"},{"key":"cit0198","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14322"},{"key":"cit0199","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"cit0200","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"cit0201","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"key":"cit0202","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"cit0203","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.045"},{"key":"cit0204","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14871"},{"key":"cit0205","unstructured":"Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema). https:\/\/ClinicalTrials.gov\/show\/NCT02001181."},{"key":"cit0206","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16014"},{"key":"cit0207","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015"},{"key":"cit0208","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.004"},{"key":"cit0209","unstructured":"Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg\/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03725722."},{"key":"cit0210","unstructured":"Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children. https:\/\/ClinicalTrials.gov\/show\/NCT03826901."},{"key":"cit0211","unstructured":"A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT02925117."},{"key":"cit0212","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"cit0213","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.918604"},{"key":"cit0214","unstructured":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03568318."},{"key":"cit0215","unstructured":"Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema). https:\/\/ClinicalTrials.gov\/show\/NCT03569293."},{"key":"cit0216","unstructured":"A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2). https:\/\/ClinicalTrials.gov\/show\/NCT03607422."},{"key":"cit0217","unstructured":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03646604."},{"key":"cit0218","unstructured":"A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03661138."},{"key":"cit0219","unstructured":"A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03738397."},{"key":"cit0220","unstructured":"Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT04195698."},{"key":"cit0221","unstructured":"AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ\u2122 (upadacitinib) in Atopic Dermatitis [Internet]. PRNewswire; 2020"},{"key":"cit0222","unstructured":"AbbVie\u2019s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis [Internet]. PRNewswire; 2020"},{"key":"cit0223","unstructured":"Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT02780167."},{"key":"cit0224","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"cit0225","unstructured":"Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03349060."},{"key":"cit0226","unstructured":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03422822."},{"key":"cit0227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"cit0228","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"cit0229","unstructured":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy. https:\/\/ClinicalTrials.gov\/show\/NCT03720470."},{"key":"cit0230","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"cit0231","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.169"},{"key":"cit0232","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0723-3"},{"key":"cit0233","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019839650"},{"key":"cit0234","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"cit0235","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"cit0236","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.015"},{"key":"cit0237","unstructured":"A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT02576938."},{"key":"cit0238","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"cit0239","unstructured":"A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03334435."},{"key":"cit0240","unstructured":"A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not MedicallyAdvisable . https:\/\/ClinicalTrials.gov\/show\/NCT03428100."},{"key":"cit0241","unstructured":"A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03435081."},{"key":"cit0242","unstructured":"A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03559270."},{"key":"cit0243","unstructured":"A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03952559."},{"key":"cit0244","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0653"},{"key":"cit0245","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000446"},{"key":"cit0246","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145"},{"key":"cit0247","first-page":"75","volume":"8","author":"Raedler LA","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"cit0248","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.040"},{"key":"cit0249","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790"},{"key":"cit0250","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016"},{"key":"cit0251","volume-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase","volume":"2","author":"Cotter C","year":"2020"},{"key":"cit0252","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"},{"key":"cit0253","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"cit0254","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12489"},{"key":"cit0255","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2017.10.005"},{"key":"cit0256","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.04.008"},{"key":"cit0257","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1220"},{"key":"cit0258","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11000.x"},{"key":"cit0259","unstructured":"A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis.https:\/\/ClinicalTrials.gov\/show\/NCT03257644."},{"key":"cit0260","unstructured":"A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03920852."},{"key":"cit0261","unstructured":"A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03011892."},{"key":"cit0262","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"cit0263","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.009"},{"key":"cit0264","doi-asserted-by":"publisher","DOI":"10.25251\/skin.4.supp.95"},{"key":"cit0265","unstructured":"TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis. https:\/\/ClinicalTrials.gov\/show\/NCT03745638."},{"key":"cit0266","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.16.9630"},{"key":"cit0267","unstructured":"Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019 [Internet]. GlobeNewswire; 2018"},{"key":"cit0268","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-4204"},{"key":"cit0269","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-792"},{"key":"cit0270","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17932"},{"key":"cit0271","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.567"},{"key":"cit0272","unstructured":"Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT). https:\/\/ClinicalTrials.gov\/show\/NCT03531957."},{"key":"cit0273","unstructured":"Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo. https:\/\/ClinicalTrials.gov\/show\/NCT04103060."},{"key":"cit0274","author":"Piscitelli S","year":"2018","journal-title":"Exp Dermatol"},{"key":"cit0275","unstructured":"Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit [Internet]. 2018"},{"key":"cit0276","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70246-4"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2021.1940962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T10:22:05Z","timestamp":1646130125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2021.1940962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":276,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/1744666X.2021.1940962"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2021.1940962","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}